Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -Institution
Address of institution - Street address
Address of institution - City
Address of institution - Postcode
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?Alzheimer's disease and other dementias||Neurodegenerative disease in general
Q1b. When are studies on the above condition(s) expected to become possible?
Q2a. In a single sentence what is the stated aim of the cohort?To increase our understanding of the aging process and to identify preventive strategies that can lead to improved health and care of the elderly.
Q2b. What distinguishes this cohort from other population cohorts?
Q3a. i) Number of publications that involve use of your cohort to date
Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)Fratiglioni, et al. An active and socially integrated lifestyle in late life might protect against dementia. The Lancet Neurology. 2004| Rizzuto, et al. Lifestyle, social factors, and survival after age 75: population based study. BMJ. 2012.| Qiu C Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden.
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly availableData are avalible on request
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:
Q4a. Study criteria: what is the age range of participants at recruitment? To:
Q4b. Study criteria: what are the inclusion criteria?75 years or older and living in Kungsholmen area, Stockholm
Q4c. Study criteria: what are the exclusion criteria?
Q5. What is the size of the cohort (i.e. how many participants have enrolled)?
Q6a. Please describe what measures are used to characterise participantssocial interview, physical functioning, clinical examination, including geriatric, neurological and psychiatric assessment, cognitive assessment.
Q6b. Are there additional measures for participants with a clinical disorder?Proxy interview in case of cognitive impairment
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
Q7. What is the study design (select all that apply)?
Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Q10a. i) Please enter the data collection start date
Q10a. ii) Please enter the data collection end date
Q10a. iii) Is data collection for this studyData analysis ongoing| Closed to new patients
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Q11. Is data collectedThrough links to medical records
Other please specify here
Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?
Q13a. Please give information on the format and availability of data stored in a database (1)Data summarised in database
Q13a. Please give information on the format and availability of data stored in a database (2)
Q13a. Please give information on the format and availability of data stored in a database (3)Database on spreadsheet (e.g. excel)
Q13a. Please give information on the format and availability of data stored in a database (4)
Q13b. Please give information on the format and availability of data held as individual records (1)Data is held as individual records
Q13b. Please give information on the format and availability of data held as individual records (2)
Q13b. Please give information on the format and availability of data held as individual records (3)Data held on computer based records
Q13b. Please give information on the format and availability of data held as individual records (4)
Please specify language used
Q14a. Is data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?Apply to PI or co-ordinator at resource| Access independent of collaboration with PI| Local/ regional access| National access| International access| Access for pilot studies permitted| RAccess restricted to peer-reviewed work| Resource has own ethics approval so usually no need for separate external ethics approval
Q15. What data sharing policy is specified as a condition of use?Data made publicly available after a specified time point
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below:Living donors: blood| Living donors: blood derivatives| Living donors: DNA
Q16b. ii) In what form are tissues/samples/DNA supplied?Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples:(derivatives of primary samples)| Secondary samples: plasma| Secondary samples: DNA
Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?
Types: Population Cohorts
Member States: Sweden
Diseases: Alzheimer's disease & other dementias, Neurodegenerative disease in general
Years: 2016
Database Categories: N/A
Database Tags: N/A
Export as PDF
